Fulgent Genetics Inc (FLGT) posted $90.4 million in Q3 2026 revenue, narrowed its non-GAAP loss guidance on disciplined spending, and advanced its AI pathology and therapeutic development initiatives.
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +86.15% and +4.77%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Precipio Inc (PRPO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.